X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA CIPLA ALEMBIC PHARMA/
CIPLA
 
P/E (TTM) x 25.2 39.3 64.2% View Chart
P/BV x 5.1 3.6 140.8% View Chart
Dividend Yield % 0.7 0.5 142.3%  

Financials

 ALEMBIC PHARMA   CIPLA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
CIPLA
Mar-18
ALEMBIC PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs645663 97.3%   
Low Rs470479 98.1%   
Sales per share (Unadj.) Rs166.1189.0 87.9%  
Earnings per share (Unadj.) Rs21.917.6 124.5%  
Cash flow per share (Unadj.) Rs27.534.0 80.8%  
Dividends per share (Unadj.) Rs4.003.00 133.3%  
Dividend yield (eoy) %0.70.5 136.6%  
Book value per share (Unadj.) Rs117.8176.7 66.6%  
Shares outstanding (eoy) m188.52805.12 23.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 111.1%   
Avg P/E ratio x25.532.5 78.4%  
P/CF ratio (eoy) x20.316.8 120.8%  
Price / Book Value ratio x4.73.2 146.5%  
Dividend payout %18.317.1 107.1%   
Avg Mkt Cap Rs m105,090459,724 22.9%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m6,22826,901 23.2%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m31,308152,193 20.6%  
Other income Rs m703,577 2.0%   
Total revenues Rs m31,378155,769 20.1%   
Gross profit Rs m6,43128,264 22.8%  
Depreciation Rs m1,05513,228 8.0%   
Interest Rs m341,142 3.0%   
Profit before tax Rs m5,41317,470 31.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-81-28 291.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m1,2042,501 48.1%   
Profit after tax Rs m4,12814,166 29.1%  
Gross profit margin %20.518.6 110.6%  
Effective tax rate %22.214.3 155.3%   
Net profit margin %13.29.3 141.7%  
BALANCE SHEET DATA
Current assets Rs m18,247108,141 16.9%   
Current liabilities Rs m11,23538,322 29.3%   
Net working cap to sales %22.445.9 48.8%  
Current ratio x1.62.8 57.6%  
Inventory Days Days8697 88.2%  
Debtors Days Days6174 82.5%  
Net fixed assets Rs m20,035109,411 18.3%   
Share capital Rs m3771,610 23.4%   
"Free" reserves Rs m21,824140,682 15.5%   
Net worth Rs m22,201142,292 15.6%   
Long term debt Rs m5,00036,621 13.7%   
Total assets Rs m39,411228,606 17.2%  
Interest coverage x160.216.3 983.2%   
Debt to equity ratio x0.20.3 87.5%  
Sales to assets ratio x0.80.7 119.3%   
Return on assets %10.66.7 157.7%  
Return on equity %18.610.0 186.8%  
Return on capital %19.710.0 198.2%  
Exports to sales %46.432.8 141.6%   
Imports to sales %10.50-   
Exports (fob) Rs m14,53549,883 29.1%   
Imports (cif) Rs m3,288NA-   
Fx inflow Rs m14,72251,691 28.5%   
Fx outflow Rs m7,02621,033 33.4%   
Net fx Rs m7,69630,658 25.1%   
CASH FLOW
From Operations Rs m3,12414,628 21.4%  
From Investments Rs m-8,844-8,540 103.6%  
From Financial Activity Rs m5,026-3,855 -130.4%  
Net Cashflow Rs m-6932,431 -28.5%  

Share Holding

Indian Promoters % 74.1 16.0 463.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.9 12.2 23.8%  
FIIs % 9.1 23.7 38.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 13.9 26.2 53.1%  
Shareholders   49,328 161,166 30.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 297 Points Higher; Energy and Realty Stocks Witness Buying(Closing)

Share markets in India continued their momentum during closing hours and ended the day on a positive note. Sectoral indices were trading on a positive note, with stocks in the energy sector.

Related Views on News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Oct 16, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS